The standardized uptake value calculated from <sup>111</sup>In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by <sup>90</sup>Y- ibritumomab tiuxetan therapy-Reference-Cited by-同舟云学术

The standardized uptake value calculated from ¹¹¹In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by ⁹⁰Y- ibritumomab tiuxetan therapy

Published:2021 Issue:1 Volume:61 Page:29-34
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Kume Ayaka¹,Toriihara Akira²,Shimizu Ryo¹,Harata Naoki³,Isogai Jun³,Tanaka Hiroaki¹

Affiliation:

1. Department of Hematology, Asahi General Hospital, Chiba, Japan,

2. PET Imaging Center, Asahi General Hospital, Chiba, Japan,

3. Department of Radiology, Asahi General Hospital, Chiba, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/61/1/61_20055/_pdf

Reference13 articles.

1. 1 Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; 2: 457-470.

2. 2 Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002; 20: 2453-2463.

3. 3 Tobinai K, Watanabe T, Ogura M et al. Japanese phase II study of 90 Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009; 100: 158-164.

4. 4 Witzig TE, Molina A, Gordon LI et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007; 109: 1804-1810.

5. 5 Uike N, Choi I, Tsuda M et al. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. Int J Hematol. 2014; 100: 386-392.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetry with single photon emission tomography (SPECT);Nuclear Medicine and Molecular Imaging;2022